Get the Stockscreener App
95.89
4.49%
-4.51
After Hours:
95.00
-0.89
-0.93%
Grail Inc stock is traded at $95.89, with a volume of 738.04K.
It is down -4.49% in the last 24 hours and down -9.48% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$100.40
Open:
$100.42
24h Volume:
738.04K
Relative Volume:
0.82
Market Cap:
$3.74B
Revenue:
$117.67M
Net Income/Loss:
$-1.88B
P/E Ratio:
-1.584
EPS:
-60.5369
Net Cash Flow:
$-621.36M
1W Performance:
+1.95%
1M Performance:
-9.48%
6M Performance:
+185.39%
1Y Performance:
+144.24%
1-Day Range:
$92.50
$101.06
1-Week Range:
$92.50
$106.00
52-Week Range:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
95.89 | 3.91B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
Why analysts recommend GRAIL Inc. (NL0) stockJuly 2025 Update & Capital Protection Trade Alerts - mfd.ru
GRAIL Inc (GRAL) Shares Up 5.15% on Feb 10 - GuruFocus
GRAIL, Inc. (GRAL) Stock Analysis: Healthcare Innovator With Potential 14.54% Upside - DirectorsTalk Interviews
GRAIL submits FDA PMA for Galleri multi-cancer early detection test - MSN
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. - Barron's
Moloney Securities Asset Management LLC Has $959,000 Stock Holdings in GRAIL, Inc. $GRAL - MarketBeat
A $700 blood test promises to detect 50 different kinds of cancer. The results come with major caveats. - Business Insider
GRAIL, Inc. $GRAL Shares Purchased by Allianz Asset Management GmbH - MarketBeat
What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders - Sahm
Is It Too Late To Consider GRAIL (GRAL) After A 186% One Year Surge? - Yahoo Finance
How The GRAIL (GRAL) Story Is Shifting With Galleri And New Valuation Clues - Yahoo Finance
Hims & Hers Launches GRAIL Multi Cancer Screening Test - GuruFocus
Hims Briefly Pops, And Then Dives, After Scoring A Key Deal - Investor's Business Daily
Hims & Hers Shares In The Spotlight After Launching Multi-Cancer Test - Benzinga
Hims & Hers rolls out GRAIL’s multi cancer screening test - Seeking Alpha
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care - Hims Investor Relations
Hims adds cancer detection test to Labs product - Sherwood News
GRAIL, Inc. (GRAL) Investor Outlook: A Healthcare Innovator With 10.93% Upside Potential - DirectorsTalk Interviews
GRAIL Inc (GRAL) Shares Up 3.77% on Feb 2 - GuruFocus
Grail files for FDA approval of multi-cancer early detection test - MedTech Dive
Y Intercept Hong Kong Ltd Purchases Shares of 14,959 GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc.'s (NASDAQ:GRAL) Institutional Investors Lost 13% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
GRAIL (GRAL) Price Target Increased by 46.34% to 91.80 - MSN
GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test - Patient Care Online
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test - sharewise.com
GRAIL (GRAL) Is Down 13.0% After Final PMA Module Filing for Galleri Multi-Cancer Test - Sahm
Trifecta Capital Advisors LLC Purchases 10,250 Shares of GRAIL, Inc. $GRAL - MarketBeat
Grail Submits Premarket Approval Application to FDA for Multi-Cancer Early Detection Test - marketscreener.com
Grail raised to Buy at Guggenheim on potential of Galleri - MSN
Grail submits FDA premarket approval appplication for Galleri - TipRanks
GRAIL's Galleri multi-cancer test takes key step toward FDA approval - stocktitan.net
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - Prime Publishers, Inc.
Assessing GRAIL (GRAL) Valuation After Analyst Upgrades And Strong Recent Shareholder Returns - simplywall.st
GRAIL Inc (GRAL) Trading Down 7.75% on Jan 28 - GuruFocus
Multi Cancer Early Detection Market Is Going to Boom |• GRAIL • Freenome • Thrive Earlier Detection - openPR.com
Why (GRAL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Beyond The Numbers: 4 Analysts Discuss GRAIL Stock - Benzinga
GRAIL Inc.: Strong Galleri Momentum and Upcoming Regulatory Catalysts Support Buy Rating and $105 Target - TipRanks
Guggenheim Raises GRAIL (GRAL) Price Target to $130 | GRAL Stock News - GuruFocus
Why GRAIL Inc Shares Are Surging Higher Now - TipRanks
Grail price target raised to $130 from $100 at Guggenheim - TipRanks
How Is The Market Feeling About GRAIL Inc? - Benzinga
Canaccord Genuity reiterates Buy rating on GRAIL stock with $105 target - Investing.com
GRAIL Stock (-9.6%) : Guidance Disappoints + Valuation Reset - Trefis
GRAIL (NASDAQ:GRAL) Trading Down 7.7%Here's Why - MarketBeat
Why GRAIL Inc Shares Are Sliding Despite Guidance - TipRanks
No News JSON Data Available - StocksToTrade
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus - TechStock²
Here's Why This Exciting Healthcare Stock Popped 13% Today - AOL.com
Here's Why This Exciting Healthcare Stock Popped 13% Today - The Motley Fool
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):